PURPOSE: To test for a possible correlation between high-grade acute organ toxicity during primary radiochemotherapy and treatment outcome for patients with anal carcinoma. METHODS AND MATERIALS: From 1991 to 2009, 72 patients with anal carcinoma were treated at our department (10 patients had stage I, 28 patients had stage II, 11 patients had stage IIIA, and 13 patients had stage IIIB cancer [Union Internationale Contre le Cancer criteria]). All patients received normofractionated (1.8 Gy/day, five times/week) whole-pelvis irradiation including iliac and inguinal lymph nodes with a cumulative dose of 50.4 Gy. Concomitant chemotherapy regimen consisted of two cycles of 5-fluorouracil (1,000 mg/m(2)total body surface area (TBSA)/day as continuous intravenous infusion on days 1-4 and 29-32) and mitomycin C (10 mg/m(2)/TBSA, intravenously on days 1 and 29). Toxicity during treatment was monitored weekly, and any incidence of Common Toxicity Criteria (CTC) grade of ≥3 for skin reaction, cystitis, proctitis, or enteritis was assessed as high-grade acute organ toxicity for later analysis. RESULTS: We found significant correlation between high-grade acute organ toxicity and overall survival, locoregional control, and stoma-free survival, which was independent in multivariate analysis from other possible prognostic factors: patients with a CTC acute organ toxicity grade of ≥3 had a 5-year overall survival rate of 97% compared to 30% in patients without (p < 0.01, multivariate analysis; 97% vs. 48%, p = 0.03 for locoregional control, and 95% vs. 59%, p = 0.05 for stoma-free survival). CONCLUSIONS: Our data indicate that normal tissue and tumor tissue may behave similarly with respect to treatment response, since high-grade acute organ toxicity during radiochemotherapy showed itself to be an independent prognostic marker in our patient population. This hypothesis should be further analyzed by using biomolecular and clinical levels in future clinical trials.
PURPOSE: To test for a possible correlation between high-grade acute organ toxicity during primary radiochemotherapy and treatment outcome for patients with anal carcinoma. METHODS AND MATERIALS: From 1991 to 2009, 72 patients with anal carcinoma were treated at our department (10 patients had stage I, 28 patients had stage II, 11 patients had stage IIIA, and 13 patients had stage IIIB cancer [Union Internationale Contre le Cancer criteria]). All patients received normofractionated (1.8 Gy/day, five times/week) whole-pelvis irradiation including iliac and inguinal lymph nodes with a cumulative dose of 50.4 Gy. Concomitant chemotherapy regimen consisted of two cycles of 5-fluorouracil (1,000 mg/m(2)total body surface area (TBSA)/day as continuous intravenous infusion on days 1-4 and 29-32) and mitomycin C (10 mg/m(2)/TBSA, intravenously on days 1 and 29). Toxicity during treatment was monitored weekly, and any incidence of Common Toxicity Criteria (CTC) grade of ≥3 for skin reaction, cystitis, proctitis, or enteritis was assessed as high-grade acute organ toxicity for later analysis. RESULTS: We found significant correlation between high-grade acute organ toxicity and overall survival, locoregional control, and stoma-free survival, which was independent in multivariate analysis from other possible prognostic factors: patients with a CTC acute organ toxicity grade of ≥3 had a 5-year overall survival rate of 97% compared to 30% in patients without (p < 0.01, multivariate analysis; 97% vs. 48%, p = 0.03 for locoregional control, and 95% vs. 59%, p = 0.05 for stoma-free survival). CONCLUSIONS: Our data indicate that normal tissue and tumor tissue may behave similarly with respect to treatment response, since high-grade acute organ toxicity during radiochemotherapy showed itself to be an independent prognostic marker in our patient population. This hypothesis should be further analyzed by using biomolecular and clinical levels in future clinical trials.
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: Sebastian Zschaeck; Frank Hofheinz; Klaus Zöphel; Rebecca Bütof; Christina Jentsch; Julia Schmollack; Steffen Löck; Jörg Kotzerke; Gustavo Baretton; Jürgen Weitz; Michael Baumann; Mechthild Krause Journal: Eur J Nucl Med Mol Imaging Date: 2017-06-09 Impact factor: 9.236
Authors: Narges Tehrany; Julia Kitz; Margret Rave-Fränk; Stephan Lorenzen; Li Li; Stefan Küffer; Clemens F Hess; Peter Burfeind; Holger M Reichardt; Martin Canis; Tim Beissbarth; Hendrik A Wolff Journal: Strahlenther Onkol Date: 2015-01-10 Impact factor: 3.621
Authors: Voichita Bar-Ad; Qiang Ed Zhang; Paul M Harari; Rita Axelrod; David I Rosenthal; Andy Trotti; Christopher U Jones; Adam S Garden; Guobin Song; Robert L Foote; David Raben; George Shenouda; Sharon A Spencer; Jonathan Harris; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-26 Impact factor: 7.038
Authors: Robert Glynne-Jones; David Sebag-Montefiore; Helen M Meadows; David Cunningham; Rubina Begum; Fawzi Adab; Kim Benstead; Robert J Harte; Jill Stewart; Sandy Beare; Allan Hackshaw; Latha Kadalayil Journal: Lancet Oncol Date: 2017-02-11 Impact factor: 41.316
Authors: L Milena Beschel; Martin Leu; Sybille D Reichardt; Margret Rave-Fränk; Markus A Schirmer; Christine Stadelmann; Martin Canis; Hendrik A Wolff; Holger M Reichardt Journal: Oncotarget Date: 2016-10-04